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Abstract
Kathryn H. Wiedeman
A Proposed Evaluation Plan for Kaiser Permanente’s Diabetes Disease Management Program
(Under the direction of Bruce Perry M.D., MPH, Faculty Member)
DM is a serious and complex public health problem in the U.S. The CDC (2013) estimated that
25.8 million people, or 8.3% of the U.S. population, were suffering from DM in 2011. DM can
significantly affect patient’s quality of life. Additionally, DM places a significant economic burden
on the U.S. healthcare system.
Over the past two decades, DMPs have emerged as a promising intervention to improve health
outcomes for patients suffering from chronic conditions, such as DM, and to bend the cost curve.
DMP’s aim is to improve communication and follow-up so that patients can better manage their
chronic condition(s) to avoid costly hospital stays and emergency room visits (Fireman, Bartlett, &
Selby, 2004).
The Georgia region of Kaiser Permanente (KPGA) is a fully integrated health system that serves
260,000 members at 28 medical offices along with two specialty offices in the metropolitan
Atlanta area. The Center for Care Partnership, the population care division of KPGA, administers a
chronic disease management program (DMP), Healthy Solutions (HS). HS exists to improve and
maintain the health of chronically ill KPGA members, including patients diagnosed with diabetes
mellitus (DM), by providing health coaches via telephone who counsel members on their specific
chronic disease and aid members in starting or maintaining a physician approved self-care
management plan.
In order to determine the impact HS has on KPGA members with diabetes, an evaluation plan was
created to evaluate the impact HS has on members’ glycated hemoglobin (A1C), blood pressure,
and emergency department (ED) utilization. This capstone thoroughly details the proposed
evaluation plan created for HS by using Robert Milstein and Scott Wetterhall’s six-step framework
for program evaluation. Additionally, further evaluation questions are suggested and discussed in
order to provide a more complete picture of program performance to stakeholders.
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1. Introduction
The MPH candidate completed her practicum project at Kaiser Permanente. The Georgia
region of Kaiser Permanente (KPGA) is a fully integrated health system that serves 260,000
members at 28 medical offices along with two specialty offices in the metropolitan Atlanta area.
The Center for Care Partnership, the population care division of KPGA, administers a chronic
disease management program (DMP), Healthy Solutions (HS). HS exists to improve and maintain
the health of chronically ill KPGA members by providing health coaches via telephone who
counsel members on their specific chronic disease and aid members in starting or maintaining a
physician approved self-care management plan. HS targets members with Chronic Obstructive
Pulmonary Disease (COPD), diabetes mellitus (DM), Congestive Heart Failure (CHF), Asthma,
Chronic Kidney Disease (CKD), and End Stage Renal Disease (ESRD).
The practicum opportunity involved measuring the cost effectiveness of KPGA’s HS.
Although HS targets a variety of chronic diseases, the scope of the practicum only focused on the
DM portion of HS. Throughout the course of the practicum, the MPH candidate formulated an
evaluation plan based on current research of DMPs that measured the effectiveness of the program.
This capstone thoroughly details the evaluation plan created for the DM portion of HS by using
Robert Milstein and Scott Wetterhall’s six-step framework for program evaluation. In order to
understand the application of theory to a real-world evaluation, this paper alternates between
defining Milstein & Wetterhall’s framework for program evaluation and the application of the
framework concepts to the evaluation of HS at KPGA. A literature review, which is included in the
third step of the framework, was conducted to understand current DMP evaluation study design
methodology. The literature review focuses on how current suggestions from published literature
were used to create a DMP evaluation study design for KPGA. Additionally, further evaluation
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recommendations are suggested.
2. Background
2.1 Diabetes
DM is a serious and complex public health problem in the U.S. According to the Centers
for Disease Control and Prevention [CDC] (2012), DM causes the pancreas to stop making insulin
or to not use insulin properly, leading to high blood glucose, which can cause serious
complications or even death. The prevalence of DM has been steadily increasing since 1990,
which is alarming to public health officials. The CDC (2013) estimated that 25.8 million people, or
8.3% of the U.S. population, had been diagnosed with DM in 2011. It is also estimated that one in
three Americans will have DM by 2050 if prevalence continues to increase at the current rate
(CDC, 2012). A person who has DM is twice as likely to die when compared to the risk of a
person around the same age who does not have DM (CDC, 2012). The three major types of DM
are type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and gestational diabetes.
The focus of this paper is on T1DM and T2DM.
According to the National Diabetes Information Clearinghouse (2014), T1DM prohibits the
body from producing enough or any insulin because the body’s immune system attacks and
destroys the cells that make insulin. T1DM has often been referred to as juvenile DM because it is
generally diagnosed in childhood, although it can occur at any time (CDC, 2012). According to the
CDC (2012), only 5% of the U.S. population with DM has T1DM. The cause of T1DM is not fully
understood, but some possible risk factors for the disease are thought to be autoimmune, genetic,
or environmental (CDC, 2012). Maintaining proper insulin and healthy lifestyle management are
critical to living a high quality of life with T1DM.
According to the CDC (2012), T2DM prohibits the body from using insulin properly,
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which leads to high glucose levels in the bloodstream. T2DM accounts for approximately 95% of
the U.S. population with DM (CDC, 2012). It is widely believed that unhealthy eating habits and
decreased physical activity levels play a significant role in the onset of T2DM. Approximately
80% of people with T2DM are overweight or obese (NDIC, 2014). The CDC (2012) reports that a
healthy diet and regular physical activity along with properly taking prescribed medications help
control diabetes complications and prevent or delay the onset of T2DM.
According to the CDC (2012), T2DM disproportionately affects minorities in the U.S.
Most minorities, such as Hispanic Americans and non-Hispanic blacks, have a higher prevalence
of T2DM when compared to white, non-Hispanics. American Indians and Alaska Natives are also
at particularly high risk for developing T2DM. The challenge within minority groups is that T2DM
develops at a younger age in these populations, which puts minorities at a higher risk for
developing complications associated with T2DM. However, age seems to be strongly correlated
with T2DM because rates for the disease sharply increase with age for both sexes and for all racial
and ethnic groups (CDC, 2012).
According to the American Diabetes Association [ADA] (2014), if blood sugar levels are
not kept under control, DM can cause complications that can be debilitating to patients and
possibly lead to premature death. Adults with DM are about 2 to 4 times more likely to have heart
disease when compared to adults without diabetes. DM is the leading cause for new cases of
kidney failure and blindness. From 2005 to 2008, 4.2 million, or 28.5%, of adults with DM aged
40 years or older had diabetic retinopathy, which is an eye disease that results from damage to the
small blood vessels in the retina. DM is responsible for more than 60% of non-traumatic lowerlimb amputations. Among adults with DM, around 60% to 70% have mild to severe forms of
neuropathy, which is nerve damage caused by DM (ADA, 2014).
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DM places a significant economic burden on the U.S. health care system. The article
“Economic Costs of Diabetes in 2012” (2013) estimated that the national cost of DM in 2012 was
$245 billion, which is a 41% increase from the estimated national costs in 2007 of $174 billion.
Seventy-two percent, or $176 billion, of that national cost estimate is attributed to DM health care
costs and 28%, or $69 billion, represents reduced or lost productivity. Hospital inpatient care
represents the largest portion of medical expenditures at 43% of total medical costs. Additionally,
health care costs for patients with diabetes are very high. On average, patients with diabetes pay
$7,888 more, or 2.3 times, in excess health care costs per year when compared to their nondiabetic counterparts (“Economic costs,” 2013). The U.S. healthcare system cannot sustain the
growth in DM related health care costs. There is a great need for efforts to decrease health care
costs related to DM in U.S. healthcare system.
2.2 Disease Management Programs
Chronic conditions are extremely costly diseases to treat and greatly impact patients’
quality of life. According to the CDC (2014), eighty-four percent of health care spending was for
50% of the U.S. population who had one or more chronic condition in 2006. Additionally, chronic
diseases are the leading causes of death and disability in the U.S. (CDC, 2014). The U.S. health
care system desperately needs evidence-based interventions that can reduce death and disability
from chronic conditions and decrease health care costs associated with chronic conditions. Over
the past two decades, DMPs have emerged as a promising intervention to improve health outcomes
for patients suffering from chronic conditions, such as DM, and to bend the cost curve.
The Disease Management Association of American (DMAA) defines disease management
as a “system of coordinated healthcare interventions and communications for populations with
conditions in which patient self-care efforts are significant” (Wilson & MacDowell, 2003, p. 146).
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DMP’s aim is to improve communication and follow-up so that patients can better manage their
chronic condition(s) to avoid costly hospital stays and emergency room visits (Fireman, Bartlett, &
Selby, 2004). Generally, DMPs are aimed at high-cost conditions that require a significant amount
of patient self-care.
The unique aspect of DMPs is the emphasis placed on patient self-care in managing a
chronic condition. DM is a difficult condition to manage because it requires a significant amount
of lifestyle changes for the patient. Following a healthy diet, staying physically active, and
managing blood glucose levels are all critical lifestyle habits for managing DM. In order for these
patients to be successful in managing their condition, it is important that adequate support and
education are available to patients. Often, the knowledge and tools patients need in order to
successfully change lifestyle habits cannot be provided by patients’ physicians in one, single
appointment. Therefore, DMPs help supplement the diabetes care patients’ receive from their
physician. DMPs strive to provide more support to patients to manage DM.
3. Framework for Program Evaluation
In order to understand if programs are effective and implemented as intended, decisionmakers must evaluate programs. Evaluation is crucial to ensure that resources are being used
efficiently and that the population targeted by the program is being positively impacted. The CDC
recognized the critical need for effective program evaluation of public health programs. In 1999,
Robert Milstein and Scott Wetterhall, in collaboration with CDC working groups and other CDC
contributors, published an article in the CDC’s publication Morbidity and Mortality Weekly Report
that detailed an evaluation framework for practitioners to effectively evaluate public health
programs. According to Milstein & Wetterhall (1999), “effective program evaluation is a
systematic way to improve and account for public health actions by involving procedures that are
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useful, feasible, ethical, and accurate” (p. 1). A diagram of the framework is included in appendix
A. This capstone project will utilize the Milstein & Wetterhall (1999) framework to define and
organize crucial elements of the evaluation. The proposed evaluation is described in this paper,
with an emphasis on the development of the DMP evaluation methodology in the third step of the
framework.
3.1 Engage Stakeholders
According to Milstein & Wetterhall’s (1999) first step in the program evaluation
framework, program stakeholders must be engaged to ensure that all perspectives are taken into
consideration in the creation of the evaluation. When stakeholders are not engaged, important
aspects of program outcomes, goals, and operations might not be addressed. Therefore,
stakeholders need to be engaged in order for the evaluation to be meaningful to them and to ensure
that the results are used to either continue program success or make necessary changes. Three
important groups of stakeholders for program evaluation include those involved in program
operations, those served by the program, and primary users of evaluation (Milstein & Wetterhall,
1999).
Identifying stakeholders is an important step in ensuring the evaluation addresses all
relevant aspects of the program. The main stakeholders who are involved in program operations
for KPGA’s HS are the program manager and the DM care manager (DCM). Both stakeholders
were engaged in the evaluation. During the initial meeting with the HS program manager and the
DCM, both expressed that they were ready to understand the impact that HS has on KPGA
members with diabetes who participate in the program. KPGA members with diabetes are the
stakeholders who are served by the program. Although understanding KPGA members with
diabetes’ perspectives on the program is a crucial aspect of program evaluation, this proposed
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evaluation of HS will not be able to address this group of stakeholders due to resource constraints
and patient privacy laws. The primary user of the HS evaluation is the Director of the Center for
Care Partnership at KPGA because she can use the evaluation to make high-level program
decisions. The primary user must be informed frequently in the evaluation process and her input
needs to help shape the evaluation.
3.2 Describe the Program
Milstein and Wetterhall (1999) explain the importance of a detailed program description in
the second step of the program evaluation framework. Creating a detailed program description is
crucial in order to effectively evaluate a program. Linden & Roberts (2005) and Fitzner et al.
(2004) explain that DMP evaluations must clearly describe the program so that readers can decide
for themselves if evaluation outcomes are linked to the activities of the DMP. It is important to
describe the program in enough detail in order to ensure all relevant aspects of the program are
evaluated.
According to Milstein & Wetterhall (1999), seven critical aspects of program description
are need, activities, expected effects, resources, stage of development, context, and logic model.
The statement of need clearly describes a problem that the program aims to address. Defining
program activities ensures that strategies and actions are displayed in a logical sequence. The
expected effects, or program outcomes, are main goals that the program is trying to achieve in
order to be considered successful. Program stage of development, which can be classified into the
planning, implementation, or effects stage, must be assessed to understand program maturity.
Understanding the program’s context within the organization allows the evaluator to create an
evaluation that is sensitive to the various influences, such as political or economic influences, on
the program and stakeholders. The logic model is able to clearly summarize and link program
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processes that affect change (Milstein & Wetterhall, 1999).
As detailed in the first section, DM is an extremely expensive disease that greatly impacts
quality of life. Therefore, there is a clear need for a DM DMP at KPGA. Evidence suggests that
DM prevalence and related health care costs will continue to increase in the U.S. unless major
interventions are implemented. Due to the expenses related to DM, health plans, including KPGA,
feel it is necessary to implement interventions that prevent and manage DM for their members.
A logic model is a helpful tool that provides a clear picture of a program by linking
important program elements. The major elements of the logic model are inputs, outputs, and
outcomes. A logic model is an excellent tool to ensure that evaluation is included in each
component of the program. The program description elements of resources, activities, and
expected effects can be explained through the context of the logic model created for HS. An
illustration of the HS logic model is available in appendix B.
The HS program manager, DCM, and Director of the Center for Care Partnership are
program staff who are major program resources. Program funding is an important resource for the
success of the program. The Georgia State University MPH candidate who is creating the proposed
evaluation under the direction of the Director of the Center for Care Partnership is a program
resource. Technology, such as the electronic medical record (EMR) system and other KPGA
clinical databases are important technology resources for HS.
The HS DCM provides health coaching telephone calls to KPGA members with diabetes.
DM care management calls focus on the management of DM by covering various topics, such as
providing information about DM and support so patients can follow a physician recommended DM
self-management plan. The goal of DM care management calls is to have two calls the first month
with a new participant, then a monthly follow-up call after the first month. Participants being
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served by the program are KPGA members with a diagnosis of T1DM or T2DM with a glycated
hemoglobin, or A1C, blood test result between 8% to 9%. The A1C blood test provides an idea of
average blood glucose control over the past two to three months (ADA, 2013). Thus, this blood
test is a commonly used to monitor the management of DM.
KPGA members with diabetes access program services through a variety of avenues. KPGA
members with diabetes can contact the HS hotline to speak directly with the DCM. Physicians can

send an internal message to the DCM recommending that she reach out to a KPGA member with
diabetes. The DCM provides outreach by identifying KPGA members with diabetes who would
benefit from the program through the KPGA clinical database. The DCM provides outreach to
KPGA members with diabetes who have recently been discharged from a hospitalization due to
DM.
Program activities aim to positively influence program expected effects, or outcomes.
Generally, expected effects take place over a broad period of time. The main short-term outcome,
which is expected to take place within three months, is to increase awareness of DM and healthy
DM self-care management habits. HS aims to provide KPGA members with diabetes with the tools
to start examining their own lifestyle habits, such as diet and physical activity, and to understand
how these lifestyle habits can impact blood sugar. Within six months, the intermediate-term
outcomes of incorporating new behaviors to improve DM self-care and increasing knowledge of
DM are expected to take place. The long-term outcome, expected to take place within a year, is for
KPGA members with diabetes 65 years and older to have a controlled A1C level of 8% or less and
members younger than 65 years old to have an A1C level of 7% or less.
When evaluating a program, the stage of development must be taken into consideration to
understand program maturity. For example, a program that has just received funding will be very
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different from a well-established program. HS has been providing DM care management services
to KPGA members with diabetes since October 2012. Enough time has passed for the expected
effects of HS to take place; therefore, HS is in the effect stage of development according to
Milstein and Wetterhall (1999). The HS evaluation goal is to understand the effect of program
activities on relevant clinical and economic outcomes.
Understanding and acknowledging the context of HS will ensure that the evaluation is
sensitive to economic or political influences. A third party vendor managed KPGA’s DMP until
September 30, 2012. KPGA internalized the program on October 1, 2012 because KPGA felt they
could provide higher quality DMP services at a lower cost to the organization. KPGA is proud of
this decision and the program. Program stakeholders are confident that the program is making a
significant, positive impact on KPGA members with diabetes, but there is always a possibility that
evaluation results could show little or no program impact. Therefore, special attention will need to
be paid to reporting unfavorable evaluation results. It is important to emphasize that any program
evaluation results provide stakeholders with valuable information on the program. Results, whether
favorable or unfavorable, can be used to improve program operations and build a foundation of
continuous evaluation of the program going forward.
3.3 Focus the Evaluation Design
According to Milstein & Wetterhall’s (1999) third step of the framework, creating a
thorough evaluation plan ensures that intended uses are made known and increases the chances
that the evaluation will be useful, feasible, ethical, and accurate. The evaluation design must be
clearly defined before data collection begins because changing the evaluation design after data is
collected can be very difficult, if not impossible, to do. The following six components of focusing
the evaluation design will be explored through the context of the proposed HS evaluation: purpose,
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users, uses, questions, agreements, and methods. Having a clear evaluation purpose will allow all
decision makers to make well-informed decisions for the evaluation plan. Users are the
stakeholders who will receive the evaluation results. Uses are the specified ways the users will
apply the findings. Evaluation questions need to reflect what stakeholders are ultimately trying to
understand about the effectiveness of a program. Agreements are an evaluation outline that
clarifies stakeholder roles and responsibilities and details the resources that will be used for the
evaluation. Methods for gathering data for the evaluation are created by using opinions from
scientific research, particularly from social, behavioral, or health sciences research (Milstein &
Wetterhall, 1999). Although all six components are important in evaluation, the development of
the evaluation methodology for HS will be discussed in detail in a separate, subsequent section of
this paper. The component of evaluation questions will also be addressed in the separate methods
section.
The purpose of the HS evaluation is to assess if the program is making a positive impact on
health and economic outcomes of interest. Stakeholders want to understand if the investment of
company financial and human resources into improving KPGA members’ with diabetes health
outcomes is saving KPGA money. In order to understand this relationship, the evaluation needs to
examine the impact of HS program activities on KPGA members’ with diabetes health and
economic outcomes. Since HS is in the effects stage of development, it is appropriate to evaluate
the effect of program activities on desired health and economic outcomes.
Two main users of the evaluation will be the primary user, the Director of the Center for
Care Partnership, and the HS program manager. The primary user wants to understand the
effectiveness of HS in order to ensure financial and human resources are being allocated
appropriately to the program. The primary user is also interested in hiring additional DCM if the
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evaluation suggests that the program is effective. Additionally, the primary user will use the results
of the evaluation to show potential and existing KPGA clients the effectiveness of KPGA’s HS.
The HS program manager will use the evaluation results to improve operations and program
activities, if needed.
A verbal agreement of the evaluation plan was made between the Director of the Center for
Care Partnership and the GSU MPH candidate. A formal, written agreement was not executed for
the HS evaluation plan, but the GSU MPH candidate consulted with the primary user through
meetings and used the primary user’s input to develop the evaluation plan. Human resources that
will be needed for the evaluation are the HS program manager, HS DCM, an evaluation specialist,
a KPGA data analyst, and Director of the Center for Care Partnership. The timeframe of the
evaluation will need to be determined when the stakeholders are ready to execute the evaluation
plan. KPGA member data will need to be available in order to conduct the HS evaluation data
analysis.
3.3.1 Methods: Literature Review & Methodology Development
In order to understand if a DMP is effective, it must be evaluated. Although evaluation
takes place in research and industry, there are differences between the two. Evaluation research
aims to add to generalized knowledge often by using a randomized controlled trial (RCT) study
design. In industry, health care decision-makers want to understand if a DMP is working to ensure
that resources, such as staff and money, are being allocated properly. Unfortunately, it is difficult
to bridge the gap between research and practice. One possible explanation for this gap is that
rigorous study designs suggested in published literature are nearly impossible to use in industry
due to data, resource, and time limitations. Decision-makers run the risk of misallocating scarce
resources when making decisions on results produced from weak study designs. In order to
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perform strong evaluations that represent the actual impact of DMPs, industry must adapt as much
scientific rigor as possible when performing DMP evaluations. The study design created to
evaluate the DM portion of HS used as much of the scientific rigor suggested in the literature as
possible while working within the constraints of a real-world evaluation.
3.3.1a Outcomes of Interest
Stakeholders in the HS evaluation were most interested in the return on investment (ROI)
of HS, however, determining an accurate ROI for a DMP is very challenging. A financial ROI
calculation alone does not prove that the DMP is achieving its main goal: reducing or eliminating
major adverse health events related to a specific condition (Lewis, 2009). It is strongly suggested
that other outcomes, such as health or utilization outcomes, be taken into consideration when
evaluating a DMP (Linden & Roberts, 2005). Health care costs can be greatly influenced by
factors other than the DMP, such as members’ financial share of the medical expense (Linden &
Roberts, 2005). Therefore, it can be argued that evaluating health outcomes and health care
utilization are better measurements of program success than simply a financial ROI calculation.
After the outcomes of interest have been evaluated, the results can then be translated into an ROI
as long as some well-defined assumptions about the population have been made (Lewis, 2009).
In order to clearly define the outcomes of most interest to stakeholders, evaluation
questions must be formulated. Evaluation questions aim to answer whether or not the program is
achieving desired expected effects. Evaluation questions were created with input from stakeholders
regarding their opinion on the most important health and economic outcomes that can best measure
program effectiveness. Additionally, research on DMP methodology helped shape the following
evaluation questions:
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1.

Are there differences in A1C results between KPGA members with diabetes who
received HS health coaching and KPGA members with diabetes who did not receive HS
health coaching?

2.

Are there differences in blood pressure readings between KPGA members with diabetes
who received HS health coaching and KPGA members with diabetes who did not
receive HS health coaching?

3.

Are there differences in the number of emergency department admissions between
KPGA members with diabetes who received HS health coaching and KPGA members
with diabetes who did not receive HS health coaching?
The main goal in a DM DMP is to improve blood glucose management, which is measured

by A1C. A1C is the most important outcome measurement for HS because A1C provides an
accurate picture of blood glucose management in a population. Evaluating A1C control in the
population provides a high-level indication of the effectiveness of the program to stakeholders. It
also ensures that the end goal of successful DM self-care management is being accomplished.
Therefore, it is critical to understand the relationship between HS and KPGA members’ with
diabetes A1C levels.
The ADA (2014) reports that 67% of adults age 20 or older who reported a DM diagnosis
had blood pressure greater than or equal to 140/90 mmHg or used prescription blood pressure
lowering medication. Since DM is a major cause of heart disease and stroke (CDC, 2013), diabetic
patients with high blood pressure are at an even higher risk of an adverse cardiovascular event.
DM alone can compromise quality of life and is expensive to manage; therefore, high blood
pressure along with DM exacerbates health problems. It is important to understand if HS has an
impact on KPGA members’ with diabetes blood pressure.
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Since two measures of program effectiveness are clinical outcomes, emergency department
(ED) admissions are suggested as an economic measure of program effectiveness. DMPs can
impact health care utilization more than health care costs (Serxner et al., 2006). According to the
Agency for Healthcare Research and Quality [AHRQ] (2013), there were approximately 12.1
million DM-related ED visits for U.S. adults age 18 and older in 2010. Fifty-eight percent of these
ED visits were treatment and release. Forty-two percent of these DM-related ED visits resulted in
hospitalization while, in comparison to all ED visits, only 15.3% resulted in hospitalization. There
were 771,000 DM-related ED visits; with “DM with complications” being the most frequently,
first-listed condition for DM related ED visits (AHRQ, 2013). HS aims to provide the support and
knowledge to help KPGA members manage their diabetes and prevent ED admissions. Thus, ED
utilization is a good measure of understanding the self-management of DM in KPGA diabetes
population.
3.3.1b Study Population
According to Wilson et al. (2004), the main goal when defining the study population is to
ensure that the intervention and control population are as equivalent as possible. The more
equivalent the intervention and control population are, the more likely any impact on outcomes can
be attributed to the program. For example, if blood pressure is being analyzed between a control
group with significantly lower cardiovascular disease than the intervention group, then it will be
likely that blood pressure will be lower in the control group simply because the two groups were
not equivalent at baseline. Therefore, comparing these two groups indicates nothing about program
impact. It is recommended that the control group be chosen in the exact same way as the
intervention group (Wilson et al., 2004). In order to ensure comparability between the two groups,
identification of diabetes, age, inclusion, and exclusion criteria were clearly defined by
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recommendations in the literature for this proposed study design. A graph is located in appendix C
that illustrates the recommended study population for the HS evaluation.
Clearly defining the specifications for how DM is identified in a population is a critical first
step in creating a study design to evaluate program effectiveness. Often in DMP evaluation, simply
using International Classification of Diseases, 9th Revision (ICD-9) codes, identifies patients.
Fetterolf, Wennberg & Devries (2004) argue that using these codes alone are not sufficient in
accurately identifying the DM population. Using ICD-9 codes could lead to including patients who
do not have DM or excluding patients who do have DM into the study population. Suggested
practice is to identify patients by a variety of measures, including identifying patients by
hospitalization for DM and certain medications for DM (Fetterolf et al., 2004).
Fortunately, it is relatively straightforward to identify patients with DM in KPGA’s integrated
health care system. In order to clearly identify KPGA members who have DM, it is advised to use
an established, comprehensive strategy, such as the Health Plan Employer Data Information Set, or
HEDIS© (Fetterolf et al., 2004). HEDIS© measures performance on 81 measures of care and
service across 5 domains of care, including DM (HEDIS©, 2013). This tool is used by over 90%
of health plans in the U.S. (HEDIS©, 2013). The diagnosis of DM for the HS evaluation should
use the HEDIS Comprehensive Diabetes Care© definition. HEDIS© chooses the population with
DM through measures of outpatient, ED, and inpatient encounters by appropriate ICD-9 codes
along with the inclusion of certain DM medications. Since HEDIS© uses a variety of measures to
choose the DM population, this comprehensive definition ensures that the appropriate members
will be included in the population.
HS starts to provide DM care management telephone coaching to KPGA members’ with
diabetes at age 18. The oldest age used that needs to be used in this evaluation is 80 years old
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because HS services are available to KPGA members up to age 80. Age is defined as the age of the
patient at the BP or A1C reading and the age at the time of the ED admission.
The inclusion and exclusion of certain patients are necessary steps in study design, but it
can be challenging when trying to maintain equivalency between the intervention and control
group. To ensure comparability between the intervention and control group, the same criteria to
include and exclude patients must be applied to both the intervention and control group (Wilson et
al., 2004).
One inclusion criterion should be used in this study design. The criterion must be applied to
both the intervention and control group. HS provides services to patients age 18-80, but HEDIS©
uses 75 years old as the maximum age in the definition of DM. The inclusion criterion in this study
is to include KPGA members with diabetes that are considered diabetic based on the HEDIS
Comprehensive Diabetes Care© definition from ages 76-80 in the study population.
One exclusion criterion needs to be applied to both the intervention and control population.
KPGA has two medical office buildings (MOBs) that offer members one-on-one health coaching
with a certified DM health coach. Therefore, KPGA members with diabetes from these two MOBs
do not need to be included in the study population. Since these two MOBs are offering intensive
health coaching for DM, the diabetic populations at these MOBs could be significantly different
from the remaining MOBs in Georgia. Thus, this factor could possibly skew the results of the
study.
3.3.1c Study Design in Evaluation
In order to prove if a DMP is working, a causal pathway between the DMP and changes in
health and economic outcomes must be clearly illustrated. However, proving this causal pathway is
the most difficult part of accurately evaluating a DMP. The selection of a strong study design for
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DMP evaluation is critical in order to produce “…results [that] represent an unbiased estimate of
treatment effect” (Linden & Roberts, 2005, p. 113). When evaluating a DMP, it is always possible
that some other factor(s) besides the DMP influenced financial and clinical outcomes (Serxner,
Baker, & Gold, 2006).
One factor that can confuse the causal pathway between health outcomes and the DMP is
that HS is not the only encounter patients with diabetes have with KPGA. KPGA members with
diabetes have other providers participating in their care, such as dieticians, physicians, and nurses.
Additionally, there are other possible factors, such as a DM support group, outside of KPGA
health care that can influence DM self-care management. Therefore, it will be difficult to
determine that HS alone was responsible for changes in clinical or economic outcomes.
Currently, varying DMP evaluation study designs in the literature along with a lack of
methodology standardization make determining the financial and clinical impact of DMPs
challenging (Wilson, MacDowell, Salber, Montrose, & Hamm, 2008). These issues have led to
some skepticism when interpreting program financial impact from DMP evaluations in the
literature (Lewis, 2009). In order to achieve the scientific rigor needed to accurately develop and
use study designs to evaluate DMP programs, an array of knowledge is needed from disciplines
such as epidemiology, health services research, evaluation research, and statistics. Often,
evaluating DMPs in industry is fulfilling a business need and the individual(s) conducting the
evaluation are not experts at evaluation. This could be one possible explanation for the lack of
standardization and scientific rigor in DMP evaluation.
DMP methodology research overwhelmingly suggests that the strongest study design for
program evaluation is a randomized controlled trial (RCT). A RCT ensures both the intervention
and control group are very similar, thus increasing comparability of the two groups and the

19

likelihood that outcomes can be attributed to the DMP (Linden & Roberts, 2005). However, the
RCT is often not possible to use when evaluating DMPs in industry, mainly because the program
being evaluated has already been implemented. Additionally, there are various constraints, such as
data or resource limitations, which do not allow for rigorous study design methods in practice.
Because the RCT is nearly impossible to use in industry, the most practical study design for
DMP evaluation is the pre-post study design without a control group (“Standard outcome,” 2003).
The pre-post study design takes baseline data from a group of individuals before an intervention
and assesses the same groups’ outcomes of interest after the intervention (Fetterolf et al., 2004).
The literature is somewhat conflicting when making suggestions of the best study design
methodology. Linden & Roberts (2005) and Wilson & McDowell (2003) explain that it is
absolutely necessary to have a control group to draw conclusions about the impact of the DMP.
The relative ease and feasibility of the pre-post study design appeals to DMP stakeholders;
however, it does have significant limitations. According to Gordis (2009a), the difference in time
periods makes it difficult to determine if any clinical or financial changes are due to the DMP itself
or to factors that may have changed over time, such as improvements in health care delivery to
diabetics or improvements in DM medication. The two groups lack comparability due to the time
period difference, which makes it difficult to determine program impact because there are likely
unknown confounders that are not controlled for in this type of study design. This type of study
design can make suggestions about the impact of a program on outcomes of interest, but it cannot
prove program effectiveness (Gordis, 2009a).
3.3.1d Case-Control Study Design
The goal of this proposed evaluation study design is to use as much scientific rigor as
possible, but to work within the constraints of a real-world evaluation. Due to the impossibility of
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using a RCT and the limitations of the pre-post study design, the case-control study design is the
best option to evaluate KPGA’s DM DMP. In order to understand the exposure-outcome
relationship between HS and A1C, blood pressure, and ED utilization, a group of KPGA members
with diabetes who had contact with HS needs to be compared to a group of KPGA members with
diabetes who have not had contact with HS.
The timeframe and case-control definition development was adapted from a case-control
study that examined the impact of a diabetes health education program on A1C and lipid levels
conducted by Roblin, Ntekop, & Becker (2007). Additionally, Dr. Doug Roblin, a KPGA health
services researcher and faculty member at Georgia State University, offered his expertise in
developing this case-control study design. It is critical to have baseline, intervention, and postintervention periods in order to draw comparisons of outcome measures between the cases and
controls. The baseline period, which is suggested to span from 10/1/2013 to 3/31/2014, should
include case and control observations with an A1C or blood pressure reading and no HS contact.
The recommended timeframe for the intervention period is from 4/1/2014 to 9/30/2014. The
intervention period needs to include cases with at least one HS contact along with an A1C and
blood pressure reading. Controls must not have contact with HS, have at least one primary care
encounter, and an A1C or blood pressure reading. The post-intervention period, which is suggested
to span from 10/1/2014 to 3/31/2015, should include cases with an A1C or blood pressure reading.
Cases can have contact with HS in the post-intervention timeframe. Controls need an A1C or blood
pressure reading, but cannot have contact with HS. Members can be identified as having contact
with the program by using the DM care management code in KPGA’s EMR system along with the
DCM’s KPGA provider number. ED admission data should be collected for all cases and controls
along with the first three listed ICD-9 diagnoses for the admission to ensure that the ED visit was
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related to DM. A table of this study design is located in appendix D.
Unfortunately, data limitations do not allow the case-control study design to be used to
evaluate HS before 10/1/2013. Prior to 10/1/2013, HS used various methods to record program
data in KPGA’s EMR. The variation in data collection methods makes it impossible to use data
before October 2013 to make any accurate conclusions about program impact on KPGA members
with diabetes. When a HS call was made to a KPGA member with diabetes, the call was notated in
the members’ medical record using a specific code for a DM care management call, but that
particular code was used either if a DM care management call took place or if a voicemail
regarding program information was left for the patient. Prior to October 2013, there is no way to
determine if a patient actually received a high-quality DM care management call with the DCM.
Starting in October 2013, the DCM began to denote if she left a message for a member or if the
DM care management call was a quality call in KPGA’s EMR. When evaluating program
outcomes starting after October 2013, the new method of denoting quality calls in KPGA’s EMR
ensures that only quality calls will be used in future evaluations. This improvement in data quality
will allow KPGA stakeholders to make accurate conclusion about program impact.
In addition to collecting health and economic data for the evaluation, the demographic and
other relevant program data should be collected. Age, sex, and ethnicity need to be collected for
each case and control observation in order to understand the demographics of the cases and
controls. The number of contacts that cases have with HS during the HS and post-intervention
timeframe should be collected to assess if a dose-response relationship is present between the
exposure and the outcomes. It is important to understand if more contacts with HS result in greater
improvements in A1C and blood pressure along with lower ER utilization for DM. The number of
primary care visits for cases and controls should be collected in order to better understand the
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health care utilization habits of the cases and controls. Visits are considered primary care if they
take place in adult medicine, OBGYN, or pediatrics.
3.3.1e Challenges to Address in the Case-control Study Design
In evaluation, bias can be defined as error in the study design or the analysis that results in
a mistaken interpretation of the program impact on outcomes (Gordis, 2009b). The literature
overwhelmingly recommends that potential biases need to be recognized and steps to minimize
bias must be taken. Bias is an issue in all types of study designs, so it must be addressed before
subjects are selected for the analysis (Wilson & MacDowell, 2003). Selection and exclusion bias
are the main biases that threaten the validity of the HS evaluation. The goal is to have an
intervention and control group that are very similar. Because a RCT could not be used in the HS
evaluation, it is likely that the intervention and control group were different. Nevertheless, steps
were taken in order to minimize the effects of bias.
Selection bias enters into this evaluation because patients self-selected to participate in HS.
For many different reasons, some people are more motivated to seek health care or perform healthrelated behaviors than others (Linden & Roberts, 2005). It is possible that members who decide to
participate in HS are more motivated to improve health-related behavior than members in the
control group, thus resulting in a perceived program impact. This proposed study aims to choose
cases and controls that are roughly at the same level of willingness to change. In the intervention
period, cases should be selected based on having contact with HS and controls should be selected
based on having a primary care encounter. Cases and controls should be selected in this manner to
ensure that both groups of members are likely to make behavior changes to improve their health. If
a control attends a PCP appointment and receives the recommended A1C screenings or blood
pressure readings, then it can be assumed that these patients are, at least, somewhat willing to
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manage their DM.
Exclusion bias can be a concern in a case-control study design. Exclusion bias results when
eligibility criteria are not applied equally in the cases and the controls (Gordis, 2009b). Wilson et
al. (2004) explain that the same criteria used to identify the group who is exposed must be applied
to the reference group to ensure equivalence between the two groups. This proposed study design
to evaluate HS emphasizes that inclusion and exclusion criteria must be applied equally to both the
intervention and control group so that the two groups could be as similar as possible, thus
minimizing exclusion bias.
A significant challenge when trying to decide if a DMP actually has an impact on patient
clinical or economic outcomes is the phenomenon of regression to the mean. Regression to the
mean is defined as “a statistical property of populations... [when] individuals with extreme values
one year…tend to move toward the population average the following year” (“Standard Outcome”,
2003, p. 126). In theory, the sickest patients are more likely to get better with time while the
healthier patients are more likely to be sicker with time (Fetterolf et al., 2004). If analysis suggests
that the DMP has made improvements in the population of interest, an investigator might draw the
conclusion that the DMP is making a positive impact on the population when, in reality, regression
to the mean is taking place. Linden & Roberts (2005) suggest that it can take at least 6 months for
the desired behavior changes to take place within the population who received the DMP
intervention, so improvements in clinical or economic outcomes within one year are likely due to
regression to the mean. Increasing the study timeframe can mitigate regression to the mean. The
proposed study suggests a timeframe of a year and six months, which should minimize the effects
of regression to the mean.
Often, confounding enters into a study design and causes error in the interpretation of data.
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Confounding can confuse the exposure-outcome relationship and lead to incorrect conclusions
about the impact of a program. Confounders can cause investigators “to observe a true association
[and then] to derive a causal inference, when in fact, the relationship may not be causal” (Gordis,
2009b, p. 251). When evaluating a DMP, it is difficult to understand if a confounder, such as age,
sex, or comorbidities, or the DMP is causing an impact on clinical or economic outcomes.
Confounders are best controlled for in an RCT because “…random distribution of unmeasured
factors cancels out their impact on the study results” (Wilson et al., 2004, p. 618).
A case-control study design can control for some known confounders through the process
of matching. According to Gordis (2009b), matching cases to controls is an appropriate method to
control for confounders in a case-control study design. Gordis (2009a) defines matching as “the
process of selecting the controls so that they are similar to the cases in certain characteristics, such
as age, race, sex, or socioeconomic status, and occupation” (p. 186). Matching helps to control for
characteristics that can possibly confuse the true association between the DMP and its impact on
patient health and economic outcomes. For example, KPGA members with diabetes who received
HS services (cases) could be matched to KPGA members with diabetes who did not receive HS
services (controls) based on age. After matching in this manner, if an association is observed
between the cases and the controls, then it is unlikely that the association can be attributed to age.
Careful attention needs to be made not to match based on too many characteristics because it can
make it difficult or impossible to match a control to a case (Gordis, 2009a). Therefore, it is
important to thoroughly research which factors might be possible, significant confounders in the
analysis.
3.4 Gather Credible Evidence
According to Milstein and Wetterhall’s (1999) fourth step of the program evaluation

	
  

25

framework, gathering credible evidence increases the likelihood that stakeholders will view the
evaluation results as valuable and use the results to improve the program. If credible evidence is
not gathered for an evaluation, DMP stakeholders could make decisions based on weak data and
possibly misallocate scarce program resources. Milstein & Wetterhall (1999) suggest five aspects
of data gathering that can impact evaluation credibility: indicators, sources, quality, quantity, and
logistics. Indicators are meaningful measures of program attributes that provide an indication of
program effectiveness. Sources in an evaluation indicate where the data originated from, such as
documents or observations. It is encouraged to use multiple evaluation indicators and sources in
order to enhance the quality of the evaluation. Quality refers to the reliability of the data collected
for the evaluation. Quantity refers to the amount of evaluation data that is to be collected. Defining
logistics outlines how the evaluation data will be collected and handled (Milstein & Wetterhall,
1999).
Indicators are considered good measures to judge whether a program is successful or not.
Indicators that can be used in the HS evaluation need to measure the impact program activities
have on program effects. As detailed in the methods section, A1C and blood pressure readings
along with ED utilization are the three main indicators suggested for the HS evaluation. These
indicators are good measures for program success because when members with diabetes
successfully self-manage diabetes, A1C levels and BP will likely be controlled and ED admissions
due to diabetes complications will likely be prevented.
The source for the data will be KPGA’s EMR. For the purposes of this proposed
evaluation, only one data source is suggested in this particular evaluation. KPGA is an integrated
medical system, which allows patient care to be more coordinated and communication to be more
fluid between the health plan and health care providers. KPGA uses an EMR system, which allows
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member data to be easily accessible and updated in real-time. These factors along with the new
method of denoting quality DM care management calls will provide high quality data for the
evaluation. Since the control and intervention groups will be selected after they meet a specific set
of criteria for the HS evaluation, it will be impossible to determine the quantity of information
needed at the beginning of the evaluation. As for logistics, a data analyst, with academic and
industry experience in statistics, will be responsible for pulling the control and intervention groups
according to the specifications outlined by the GSU MPH candidate.
3.5 Justify Conclusions
Milstein & Wetterhall’s (1999) fifth step of the program evaluation framework explains
that any judgment of program performance must be justified using the evidence gathered for the
evaluation. Stakeholders are not likely to use evaluation conclusions if judgments are not linked to
evidence they deem as credible. Thus, it is important to get stakeholder buy-in of evaluation
standards at the beginning of the evaluation to ensure that conclusions will be relevant and useful
to stakeholders. Five important components for justifying conclusions include standards, analysis
and synthesis, interpretation, judgment, and recommendations. Standards reflect what stakeholders
believe are the best measures by which to judge a program. Analysis includes discovering
important trends in the data while synthesis combines other sources of information in order to
make a larger conclusion about program effectiveness. Interpretation aims to decipher what the
data indicates regarding program effectiveness. Judgments are statements about program
effectiveness that are made by comparing the findings and interpretations of the evaluation.
Recommendations are suggestions to either improve or maintain the program based on the
evaluation results (Milstein & Wetterhall, 1999).
The agreed upon standards for measuring program success in the HS evaluation include
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A1C, blood pressure, and ED admissions. For A1C, program success is defined as KPGA
members 65 years and older having an A1C of 8% or less and KPGA members 64 years and
younger with an A1C of 7% or less. Program success for blood pressure is defined as a KPGA
member with diabetes having a blood pressure reading of less than 140/90 mmHg. Program
success for ED admissions is defined as a KPGA member with diabetes not having any ED
admissions for diabetes or its related complications.
When the data for the case-control study becomes available from the KPGA data analyst,
the data analyst can then run the appropriate statistical tests to determine if there are differences in
A1C levels, blood pressure readings, and ED admissions between the cases and the controls using
a sophisticated statistical software package, such as SAS®. Synthesis can take place in this
evaluation by using the analysis along with additional sources of information to develop an ROI
for the program. Some additional sources of information that will be helpful in developing an ROI
will be program cost information along with research on average A1C levels, blood pressure
readings, and ED admissions for diabetics. The interpretation of the data will need to be completed
by the evaluation specialist and the data analyst. Program judgments will need to be made by the
evaluation specialist with input from the primary user. The recommendations to either improve or
maintain the program will need to be made by the primary user, the Director of the Center for Care
Partnership, in collaboration with the HS program manager.
3.6 Ensure and Share Lessons Learned
Milstein & Wetterhall’s (1999) sixth step in the framework suggests that appropriate
strategic planning is necessary to ensure that evaluation findings and conclusions are disseminated
and actually used. Program evaluation is a difficult and time-consuming task. Therefore, it is
important to ensure that the evaluation results are used appropriately to improve program
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operations. Five elements that can ensure and share lessons learned include design, preparation,
feedback, follow-up, and dissemination. The design of the evaluation needs to be discussed at the
onset of the evaluation and must include evaluation questions and processes along with methods.
Preparation involves thinking through the use of evaluation findings, particularly how to report
negative findings. Feedback is the process of continuously communicating with stakeholders
during the evaluation. Follow-up is the support, both technical and emotional, that the evaluator
needs to provide to the users to ensure that lessons learned from the evaluation are used to improve
the program. Dissemination is reporting the evaluation procedures and findings to relevant
audiences and stakeholders in an unbiased manner (Milstein & Wetterhall, 1999).
This paper can be used as a detailed outline of the design of the HS evaluation. Preparation
will need to be taken by the evaluator in how to most effectively report positive or negative
evaluation results to users. It will be important for users and the evaluator to provide feedback to
each other regarding the evaluation process to increase the likelihood that trust will be developed
among the team and that evaluation results will be used. The evaluator should be responsible for
following-up with users to ensure that appropriate support is provided to users so that lessons
learned from the evaluation are used to improve the program or maintain program success. In order
to effectively disseminate the evaluation, a detailed report and presentation reporting the
evaluation process and findings should be provided to users.
4. Further Evaluation Recommendations
The HS evaluation is considered an outcome evaluation because the impact of the program
on A1C, blood pressure, and ED admissions, all major health status indicators for DM, will be
analyzed. Other types of evaluation should be conducted in addition to an outcome evaluation so
that a more complete picture of program performance can be provided to stakeholders. The
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University of Wisconsin Cooperative Extension (2008) emphasizes that evaluation must be
incorporated into every component of the logic model in order to truly understand the effectiveness
of the entire program. Two additional types of evaluation that HS should focus on are process and
impact evaluation. Additional evaluation questions related to process and impact evaluation were
developed for further evaluation of HS based on the logic model. These questions should be used
as a guide to further evaluate other aspects of HS in order to enhance the outcome evaluation
already performed. The additional evaluation questions are included in appendix E.
Green & Kreuter (2005) explain that process evaluation focuses on how the program is
being implemented. It is important to understand if the program is being implemented the way it
was intended to be implemented. Process evaluation’s main goal is to understand how program
activities produce desired outcomes (Green & Kreuter, 2005). Therefore, evaluation questions
need to be developed that address program inputs and outputs.
It is important for HS stakeholders to understand the amount of resources, such as time and
money, that have been invested in the program. HS program staff should be interviewed to better
understand their input on the effectiveness of the operations of the program. Process evaluation
also aims to better understand program participants’ experience with the program. Surveys
completed by KPGA members with diabetes provide stakeholders with participants’ feedback on
the effectiveness and accessibility of activities of the program.
Green & Kreuter (2005) define impact evaluation as assessing “…the immediate effect the
program (or some aspect of it) has on target behaviors and their predisposing, enabling, and
reinforcing antecedents…” (p. 139). Some appropriate factors to take into consideration when
performing an impact evaluation include changes in knowledge, attitudes, or beliefs (Green &
Kreuter, 2005).
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An impact evaluation can be performed on the short and intermediate-term outcomes of the
HS logic model. KPGA members with diabetes who participated in the program can be surveyed to
understand if awareness of DM and healthy lifestyle habits has increased after the first three
months of starting the program. Another survey can be provided to KPGA members with diabetes
six months into the program to assess if members are able to incorporate new behaviors into their
daily routine and if knowledge has increased regarding DM.
5. Conclusion
DM is a debilitating disease that greatly compromises quality of life and is expensive to
manage. It is placing a huge burden on the U.S. healthcare system. The significant amount of selfcare required to effectively manage DM is possibly a major contributing factor for the poor
management of DM. DM self-care requires the patient to make significant behavior and lifestyle
changes. Without support and education to make difficult behavior and lifestyle changes, it is
unreasonable to expect patients with diabetes to effectively manage their condition. This gap in
DM care management in our healthcare system needs to be filled with effective programs based on
public health principals of health education and prevention. More effective programs are needed to
support patients in understanding and managing DM.
The health care industry has viewed DMPs as a promising solution to the management of
DM. Unfortunately, many studies of the effectiveness of DMPs are not performed with the
required scientific rigor needed in order to understand if these programs are effectively managing
DM. Various factors, including bias and confounding, in weak study designs threaten the internal
validity of DMP evaluations and do not allow decision makers truly to understand the impact
DMPs have on clinical and economic outcomes. More research and evaluation is needed
understand the effectiveness of DMP.
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Evaluation in industry is important, but it can be complex and challenging. Milstein &
Wetterhall (1999) insist that an evaluation must include procedures that are useful, feasible,
ethical, and accurate. When evaluating a DMP in industry, there are strong political influences that
an evaluator must work within, which can make producing an unbiased evaluation difficult.
Program stakeholders might be reluctant to complete an evaluation because they may view
judgments on program performance as a critique of their job performance. Therefore, it is
important that organizational cultures perceive evaluation as an important component in program
management. If evaluation is not being performed on industry programs, scarce resources might be
used on a program that provides little to no impact on the target population. An ineffective
program does a disservice to the population who is to benefit from the intervention. With the right
resources, such as data, evaluation planning, and expertise, industry can effectively evaluate DMPs
to ensure patients with diabetes are receiving effective interventions that improve quality of life,
prevent life-threatening diabetic complications, and decrease health care costs associated with DM.
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Appendix A
Program Evaluation Framework (Milstein & Wetterhall, 1999, p. 4)
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Appendix B
HS Logic Model
Inputs (Resources)
Program Staff:
•

1 RN DCM

•

HS Program
manager

•

Director of
Center for Care
Partnership.

Money

GSU MPH Intern

Technology
•

EMR

•

Other KPGA
clinical
databases

Outputs

Outcomes (Expected Effects)

Activities

Participants

Incoming and outgoing telephone
calls that provide diabetes care
management. Telephone calls:
• Provide information regarding
diabetes.
• Help patients weigh benefits
and risks of treatment options.
• Provide support so patients can
adhere to recommended
diabetes self-management plan.
• Connects patients to other KP
resources, such as Healthy
Living classes or nutritional
services.
• Refers patients to clinical
pharmacy services (CPS),
social services, case
management, endocrinology, or
PCP for additional care.

KPGA
members with
a diagnosis of
type 1 or 2
diabetes with
an A1C
between 8% to
9%.

Members access the program by:
• Physician referrals
• Calling the HS hotline
• Diabetes care manager outreach
• Hospital discharge referral
37

Short-term
3 Months

Intermediate
6 Months

Long-term
1 Year

Increase
awareness of
diabetes and
healthy
diabetes selfcare
management
habits.

• Behavior
modification
to
incorporate
new
behaviors to
improve
diabetes
care.

Successful
diabetes selfcare
management
of A1C for
members:

• Increased
knowledge
of diabetes
and its
disease
process.

• Younger
than 65
years old:
A1C < 7%

• 65 years or
older: A1C
< 8%

Appendix C
Study Population1

KPGA Total Member Population
Reference Population:
KPGA continuously enrolled members
with a DM diagnosis, as defined by
HEDIS©, who are 18-80 years old.

Controls:
No Healthy Solutions contact.

•
•
•
•

≤ 64 years old: A1C ≤ 8%
≥ 65 years old: A1C ≤ 7%
Blood pressure < 140/90
No ED admissions for DM.

•
•
•
•

≤ 64 years old: A1C > 8%
≥ 65 years old: A1C > 7%
Blood pressure ≥ 140/90
≥ 1 ED admission for DM.

Cases:
Healthy Solutions contact.

• ≤ 64 years old: A1C ≤ 8%
• ≥ 65 years old: A1C ≤ 7%
• Blood pressure < 140/90
• No ED admissions for DM.
•

•
•
•
•
•

≤ 64 years old: A1C > 8%
≥ 65 years old: A1C > 7%
Blood pressure ≥ 140/90
≥ 1 ED admission for DM.

1. Adapted from Gordis, L. (2009c). Case-control studies and other study designs. In L. Gordis (Ed.) Epidemiology (pp. 177200). Philadelphia: Elsevier/Saunders.
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Appendix D
Case-control Study Design for the Proposed HS Evaluation
10/1/2013 --- 3/31/2014
Baseline Period
Definition •
of Case
•
Observation
•

Definition •
of Control •
Observation
•

No HS contact
A1c result
AND/OR
BP (systolic/diastolic)
No HS contact
A1c result
AND/OR
BP (systolic/diastolic)

4/1/2014 --- 9/30/2014
Intervention Period
•
•
•
•
•
•
•

Patient receives at least one
HS contact
A1c result
AND/OR
BP (systolic/diastolic)
No HS contact
Patient receives at least one
primary care encounter.
A1c result
AND/OR
BP (systolic/diastolic)
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10/1/2014 --- 3/31/2015
Post-Intervention Period
•
•

•
•
•

A1c result
AND/OR
BP (systolic/diastolic)

No HS contact
A1c result
AND/OR
BP (systolic/diastolic)

Activities
Participants

Outputs

Process Evaluation

Inputs

Appendix E
Further Evaluation Question Recommendations1
Data Collection
Sources
Methods
Program records or
Document
existing program data.
review
Program Manager,
diabetes health coach,
Interviews
& the Center for Care
Partnership Director

Questions
What amount of time, money, and other resources were
invested in the program?

Indicators
# of staff, money used, other
resources used.

Do the program staff feel as though the program is
effective or do changes need to be made?

Program feedback from those
involved in program operations.

Do KPGA members feel they are receiving the appropriate
information regarding diabetes from the program?

#/% expressing information
relevant

KPGA members with
diabetes

Survey

Are KPGA members with diabetes able to better weight
the benefits and risks of treatment options after contact
with the program?
Are KPGA members with diabetes receiving necessary
support from the program so they can adhere to
recommended diabetes management plan?
Are KPGA members with diabetes more knowledgeable
about other KPGA resources for diabetes care
management after contact with the program, such as
Healthy Living classes or nutritional services?
Do KPGA members with diabetes who participated in the
program feel the program was helpful in the management
of their diabetes?

#/% reporting being able to
weight risks/benefits of
treatment

KPGA members with
diabetes

Survey

#/% reporting receiving
necessary support

KPGA members with
diabetes

Survey

#/% reporting being more
knowledgeable about other
KPGA resources available to
them.

KPGA members with
diabetes

Survey

#/% reporting the program as
helpful

KPGA members with
diabetes

Survey

How do KPGA members with diabetes learn about the
program?

Sources that members report
that informed them of program.

KPGA members with
diabetes

Survey

1. Adapted from University of Wisconsin Cooperative Extension (2008). Developing a logic model. [PowerPoint
slides]. Retrieved from http://www.uwex.edu/ces/pdande/evaluation/evallogicmodel.html
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Short-term
(3 months)
Intermediate-term
(6 months)

Are KPGA members with diabetes able to identify
ways to incorporate new behaviors into their daily
routine (i.e. a healthy diet or ways to increase
physical activity)?
Do KPGA members with diabetes have an
increased knowledge of diabetes and its disease
process?

Long-term
(1 year)

Outcomes

Impact Evaluation
Outcome
Evaluation

Do KPGA members with diabetes have an
increased awareness of diabetes and healthy
lifestyle habits?

Is the program successful in lowering or
maintaining KPGA members with diabetes (65
years or older) A1C at 8% or less?
Is the program successful in lowering or
maintaining KPGA members with diabetes (64
years or older) A1C at 7% or less?

#/% demonstrating increased
awareness of diabetes and healthy
lifestyle habits.

KPGA members with
diabetes

Survey

#/% reporting identification of
ways to eat healthier & increase
physical activity.

KPGA members with
diabetes

Survey

#/% demonstrating increased
knowledge of diabetes and its
disease process.

KPGA members with
diabetes

Survey

% of population maintaining A1C
of 8% or less.

Data from KPGA EMR
system.

Data
analysis

% of population maintaining A1C
of 7% or less.

Data from KPGA EMR
system.

Data
analysis

1. Adapted from University of Wisconsin Cooperative Extension (2008). Developing a logic model. [PowerPoint
slides]. Retrieved from http://www.uwex.edu/ces/pdande/evaluation/evallogicmodel.html
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